See What HealthDay Can Do For You
Contact Us

Masked HTN Common in CKD, Linked to Target Organ Damage

Masked HTN common among patients with chronic kidney disease; also linked to low eGFR, proteinuria

heart and a pump

FRIDAY, Feb. 19, 2016 (HealthDay News) -- For patients with chronic kidney disease (CKD), masked hypertension is common and is associated with reduced kidney function and cardiovascular target organ damage, according to a study published online Feb. 18 in the Clinical Journal of the American Society of Nephrology.

Paul E. Drawz, M.D., M.H.S., from the University of Minnesota in Minneapolis, and colleagues examined the correlation between masked hypertension and kidney function and markers of cardiovascular target organ damage in a cross-sectional study. They measured 24-hour ambulatory blood pressure (BP) in 1,492 men and women with CKD. Based on clinic and 24-hour ambulatory BP, participants were categorized as having controlled BP, white-coat, masked, and sustained hypertension.

The researchers found that 49.3, 4.1, 27.8, and 18.8 percent of patients had controlled BP, white-coat, masked, and sustained hypertension, respectively. Masked hypertension was independently associated with low estimated glomerular filtration rate (eGFR), higher proteinuria, and higher left ventricular mass and pulse wave velocity compared with controlled BP. Lower eGFR was seen for participants with masked hypertension only in the presence of elevated nighttime BP.

"Masked hypertension is common in patients with CKD and associated with low eGFR, proteinuria, and cardiovascular target organ damage," the authors write.

Abstract
Full Text (subscription or payment may be required)

Physician's Briefing

HealthDay

HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.